We evaluated the performance of simple logistic regression models on the tasks of predicting progression to breast cancer from the DCIS samples (n = 58, 44 non-progressors, 14 progressors), predicting the response to PD-1 inhibition in pre-treatment CTCL samples (n = 29, 14 responders, 15 non-responders) and sensitivity to postoperative treatment with hormone therapy in Estrogen and Progesterone receptor positive, HER2 negative BC samples (n = 30, 15 sensitive, 15 resistant). The gene discussed is ERBB2; the disease is breast carcinoma.